Acta Oncologica Nordic Precision Cancer Medicine Symposium 2023 - merging clinical research and standard healthcare

Affiliations

¹ MATRIX, Norwegian Centre for Clinical Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. elisa@ous-hf.no.
² Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.
³ Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Pathology, Oslo University Hospital, Oslo, Norway.
⁴ Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.
⁵ Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
⁶ MATRIX, Norwegian Centre for Clinical Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.

Editorial

Elisa Bjørgo et al. Acta Oncol. 2024.

. 2024 Jun 23:63:487-490.

doi: 10.2340/1651-226X.2024.24954.

¹ MATRIX, Norwegian Centre for Clinical Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. elisa@ous-hf.no.
² Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.
³ Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Pathology, Oslo University Hospital, Oslo, Norway.
⁴ Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.
⁵ Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
⁶ MATRIX, Norwegian Centre for Clinical Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.

No abstract available

Conflict of interest statement

No potential conflict of interest was reported by the authors.

1. Pagadala MS, Lui AJ, Zhong AY, Lynch JA, Karunamuni R, Lee KMet al. . Agent orange exposure and prostate cancer risk in the million veteran program. Acta Oncol. 2024;63:373–378. 10.2340/1651-226X.2024.25053 - DOI - PMC - PubMed
1. Niehusmann P, Leske H, Nygaard V, Russnes HG, Zhao S, Latysheva Aet al. . Desmoplastic non-infantile ganglioglioma mimicking diffuse leptomeningeal glioneuronal tumor: precision diagnostics and therapeutic implications. Acta Oncol. 2024;63:392–394. 10.2340/1651-226X.2024.31720 - DOI - PubMed
1. Otterlei Fjørtoft M, Huse K, Rye IH. The tumor immune microenvironment in breast cancer progression. Acta Oncol. 2024;63:359–367. 10.2340/1651-226X.2024.33008 - DOI - PMC - PubMed
1. Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KAet al. . Rationale and design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2018;2018:10.1200. 10.1200/PO.18.00122 - DOI - PMC - PubMed
1. ASCO TAPUR results: https://society.asco.org/research-data/tapur-study/study-results.